M&A

Top and emerging locations for M&A deals in the pharmaceutical industry

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

The data shows that M&A activity is strongest in the US, which saw a total of 19 deals announced in Q1 2022.

Powered by 

New figures released by GlobalData have shed light on the top locations for mergers and acquisitions in the pharmaceuticals industry.

The data shows that M&A activity is strongest in the US, which saw a total of 19 deals announced in the most recent quarter (2022 Q1). That's down from 20 deals announced in the previous quarter (2021 Q4).

India also performed well over the most recent quarter, with 11 deals (up from six in 2021 Q4).

Which countries are emerging as M&A powerhouses?

As well as being a top location for M&A dealmaking in the pharmaceuticals industry, India has also seen the largest uptick in recent months. The country has seen 15 deals announced over the last two complete quarters, up from an average of just eight deals every six months between 2019 and 2021.

That's the largest increase in M&A dealmaking in the pharmaceuticals industry for any country.

Despite being a top location for M&A dealmaking in the pharmaceuticals industry, the US has had a difficult few months, with just 28 deals announced in the last two complete quarters.

That's a decrease compared the country's average of 58 deals announced every six months between 2019 and 2021, and the sharpest decrease in M&A dealmaking in the pharmaceuticals industry experienced by any country in recent months.

Globally, the situation is looking distinctly positive for mergers and acquisitions in the pharmaceuticals industry.

A total of 125 deals were announced in the last quarter, up from 99 deals in the previous quarter and from an average of 76 deals per quarter over the previous three years.

GlobalData's Deals database

GlobalData tracks the performance and activities of more than 675,000 companies in over 200 countries around the world.

The data analytics firm's deals database includes the details of approximately one million deals, ranging from mergers and acquisition to venture capital financing, equity offerings and debt offerings.

Go to article: Home | Continuous manufacturing cautiously builds on hypeGo to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: WR GraceGo to article: CommentGo to article: CMO agreements need to go public, but ‘glib’ onshoring not the answerGo to article: Biologic sales forecast to pass innovative small molecule sales in next five yeaGo to article: The telemedicine community has rallied to provide support to patients in UkraineGo to article: Osteoarthritis pipeline shifting from analgesics to disease-modifying treatmentsGo to article: BioLife SolutionsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: Continuous manufacturing builds on hype but adoption remains gradual Go to article: Can Relmada’s fast-acting pill for major depressive disorder compete inGo to article: Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compaGo to article: How ambitious are the emissions targets of pharma and biotech companies?Go to article: Should Covid-19 clinical trial plans still centre around EUAs?Go to article: BEA TechnologiesGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: Top and emerging locations for M&A deals in the pharma industryGo to article: Deals relating to genomics increased in the pharma industry in H2 2021Go to article: Pharma industry companies are increasingly innovating in machine learningGo to article: BaxterGo to article: EventsGo to article: Next issue